Armata Pharmaceuticals Reports $54.9 Million Q3 Net Income, Advances AP-SA02 Phase 3 Preparations

Armata Pharmaceuticals reported third-quarter 2026 net income of $54.9 million, compared with a $26.7 million net loss a year earlier, primarily reflecting a noncash gain from changes in the fair value of its convertible loan. Grant and award revenue rose to $3.2 million, while the company reported…